Faricimab injections for persistent wet age-related macular degeneration
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a new eye drop-free injection medication called faricimab for people with wet age-related macular degeneration who haven't improved enough on standard anti-VEGF shots. The goal is to see if it can reduce fluid and improve vision better than usual treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 50 and 80 years old
- You have wet age-related macular degeneration (a type of AMD that causes abnormal blood vessels in the back of the eye)
- You have already tried at least 4 to 6 anti-VEGF injections (like Eylea or Lucentis) and your retina still has fluid or swelling
- Your vision is moderately reduced (roughly 20/40 to 20/320)
- You do not have other serious eye conditions or uncontrolled health problems like high blood pressure or diabetes
- You have not had certain eye surgeries (like laser or vitrectomy) within the last 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study observes the effects of a drug called faricimab (given as eye injections) on people with wet age-related macular degeneration (AMD), a condition causing rapid vision loss from abnormal blood vessels leaking fluid in the back of the eye. It aims to see how well the drug works when given in a specific schedule and to monitor safety and outcomes over time. This is an observational study, so you would receive the treatment as part of your normal care, and the research team will collect data.
This trial tests a new medicine called VIS-101, given as an injection into the eye, for people with wet age-related macular degeneration (AMD) who have not been treated before. The goal is to see if it can reduce fluid buildup and improve vision while being safe.
This trial tests a one-time gene therapy injection (4D-150) for wet AMD. It might help reduce the need for frequent anti-VEGF eye injections by targeting the underlying cause of new blood vessel growth.
This study tests if faricimab, an injectable eye medication, can improve vision in people with a newly diagnosed form of wet age-related macular degeneration (AMD). It is for patients who have not yet received treatment for this condition.
This trial tests if faricimab eye injections given every 3 months can keep wet age-related macular degeneration under control. It is for people with a new or returning active blood vessel growth in the center of the macula.
This study tests a medication called faricimab, given as eye injections over a long period, for people with a specific type of wet age-related macular degeneration. The goal is to see if this treatment can help maintain or improve vision over time.
Hear when a new Neovascular Age-Related Macular Degeneration (nAMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.